Crocus Laboratories


Dr. Arkadii Vaisburg is the founder and President of Crocus Laboratories Inc. (Montreal, Canada) which started its operation in 2014. Prior to that, he was the Executive Director Medicinal Chemistry at MethylGene Inc. in Montreal (currently Mirati Therapeutics in San Diego). There he created the company’s kinase chemistry platform which resulted in the discovery of multi-kinase inhibitors Glesatinib (MGCD265) undergoing phase II clinical trials and Sitravatinib (MGCD516) currently in phase I clinical trials - both in Non-Small Cell Lung Cancer. He also contributed to the development of HDAC inhibitors Mocetinostat (MGCD0103, an anticancer agent) and MGCD290 (an antifungal agent) – both reached phase II clinical trials.

Dr. Vaisburg has over 20 years of drug discovery and development experience. He is co-author of 39 scientific publications and review articles in peer-reviewed journals and co-inventor of 38 patent applications.

Dr. Vaisburg received his Ph.D. degree in Organic Chemistry from N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences in Moscow and completed his post-doctoral research at the University of Linz, Austria.

Crocus Laboratories Inc.

is seeking collaborations and partnerships with Academic Groups, Biotech
and Pharmaceutical Companies with the goal to discover and develop novel medicines.

Contact Us

Crocus Laboratories Inc. is located within the NeoMed Institute in Montreal, Canada.




Crocus Laboratories Inc.

7171 Frederick-Banting Street

Montreal, Qc, CANADA H4S 1Z9

Tel: +1-514-745-1368

Cell: +1-514-571-1474